Related Experiment Video
Updated: Jun 20, 2026
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease
Kathrin Rychli1, Kurt Huber, Johann Wojta
1Medical University of Vienna, Division of Cardiology, Department of Internal Medicine II, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Insights
Pigment epithelium-derived factor (PEDF) shows therapeutic potential for cardiovascular disease. Modulating PEDF levels may treat atherosclerosis by influencing angiogenesis and inflammation.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Biochemistry
Background:
- Pigment epithelium-derived factor (PEDF) is a protein with diverse biological functions.
- PEDF is expressed in various tissues, including the heart, and possesses antioxidant, anti-inflammatory, and antithrombotic properties.
- PEDF plays a role in regulating angiogenesis.
Purpose of the Study:
- To review the potential of PEDF as a therapeutic target for cardiovascular diseases.
- To explore the dual role of PEDF in cardiovascular disease, particularly in atherosclerosis.
- To discuss strategies for modulating PEDF activity for therapeutic benefit.
Main Methods:
- Literature review of studies on PEDF and cardiovascular disease.
- Analysis of PEDF's molecular mechanisms in atherosclerosis.
- Evaluation of PEDF's impact on angiogenesis and inflammation in the cardiovascular system.
Main Results:
- PEDF exhibits protective effects against atherosclerosis through its anti-inflammatory, antioxidant, and antithrombotic actions.
- PEDF's anti-angiogenic properties can be harnessed to inhibit lesion progression and destabilization.
- Local blockade of PEDF may promote angiogenesis in ischemic heart tissue, enhancing perfusion.
Conclusions:
- PEDF represents a promising therapeutic target for cardiovascular diseases like atherosclerosis, heart failure, and myocardial infarction.
- Strategic manipulation of PEDF levels—either blocking or overexpressing—offers potential treatment avenues.
- Further research into PEDF-based therapies could revolutionize cardiovascular disease management.
Abstract:
In this review we discuss the role of pigment epithelium-derived factor (PEDF) as a possible new target molecule to therapeutically influence cardiovascular disease. PEDF is a multifunctional, pleiotropic protein with antiangiogenic, antitumorigenic, antioxidant, anti-inflammatory, antithrombotic, neurotrophic and neuroprotective properties. First identified in retinal pigment epithelium cells, it is expressed in various tissues throughout the body such as the eye, liver and adipose tissue. Recently PEDF has also been characterized in the heart. PEDF has been suggested to have a protective role in atherosclerosis, the main cause of coronary heart disease, myocardial infarction and heart failure due to its anti-inflammatory, antioxidant and antithrombotic effects in the vessel wall and platelets. Additionally PEDF has strong antiangiogenic effects by inducing apoptosis in endothelial cells and by regulating the expression of other angiogenic factors. Therefore blocking of PEDF locally for example in ischemic tissue in the heart might favour angiogenesis, induce neovascularization and lead to increased perfusion of the injured tissue. On the other hand, local overexpression of PEDF restricted to atherosclerotic lesions might block angiogenesis, inflammation and thrombosis at these sites and thus counteract destabilization and rupture of the lesion otherwise caused by inflammatory activation and excessive angiogenesis and inhibit subsequent thrombus formation.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:22iPS Cell Differentiation